[www.elsevier.es/rcp](http://www.elsevier.es/rcp)


## Original Article

# Validity of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adult primary care users in Bucaramanga, Colombia[⋆]

## Carlos Arturo Cassiani-Miranda [a][,][∗], Angy Karina Cuadros-Cruz [b], Harold Torres-Pinzón [c]
, Orlando Scoppetta [d], Jhon Henrry Pinzón-Tarrazona [e], Wendy Yulieth López-Fuentes [e],
 Andrea Paez [b], Diego Fernando Cabanzo-Arenas [f], Sergio Ribero-Marulanda [e],
 Elkin René Llanes-Amaya [a]

a Grupo _de_ _investigación_ _Neurociencias,_ _Universidad_ _de_ _Santander_ _(UDES),_ _Bucaramanga,_ _Colombia_
b Instituto _de_ _Salud_ _de_ _Bucaramanga_ _(ISABU),_ _Hospital_ _local_ _del_ _Norte,_ _Bucaramanga,_ _Colombia_
c Grupo _de_ _Investigación_ _Salud_ _ComuniUdes,_ _Universidad_ _de_ _Santander_ _(UDES),_ _Bucaramanga,_ _Colombia_
d Universidad _Católica_ _de_ _Colombia,_ _Bogotá_ _DC,_ _Colombia_
e Universidad _Autónoma_ _de_ _Bucaramanga_ _(UNAB),_ _Floridablanca,_ _Santander,_ _Colombia_
f Facultad _de_ _Medicina,_ _Universidad_ _de_ _Santander_ _(UDES),_ _Bucaramanga,_ _Colombia_


##### a r t i c l e i n f o

_Article_ _history:_

Received 27 February 2019

Accepted 20 September 2019

Available online 20 February 2021

_Keywords:_

PHQ-9


##### a b s t r a c t

The patient health questionnaire-9 (PHQ-9) is one of the most widely used self-report

instruments in primary care. There is no criterion validity of the PHQ-9 in Colombia.


The objective was to validate the PHQ-9 as a screening tool in primary care. A cross

sectional, scale criterion validity study was performed using as reference criterion the

mini neuropsychiatric interview (MINI) in male and female adult users of primary care

centres. We calculated the internal consistency and convergent and criterion validity of


the PHQ-9 by analysing the receiver operating characteristics (ROC) and the area under


Reproducibility of results

Screening

Depression

Primary healthcare

Colombia


the curve (AUC). We analysed 243 participants; 184 (75.7%) were female. The average age


was

0.81.

AUC


34.05 (median of 31 and SD = 12.47). Cronbach’s ˛ was 0.80 and McDonald’s ω was


Spearman’s Rho was 0.64 for HADS-D (P < 0.010) and 0.70 for PHQ-2 (P <0.010). The


ity


was 0.92 (95% CI 0.880–0.963). The optimal cut-off point of PHQ-9 was ≥7: sensitiv
of 90.38 (95% CI: 81.41–99.36); specificity of 81.68 (95% CI: 75.93–87.42); PPV 57.32 (95% CI:


46.00–68.63); NPV 96.89 (95% CI: 93.90–99.88); Youden index 0.72 (95% CI: 0.62–0.82); LR+ 4.93

DOI of original article: [https://doi.org/10.1016/j.rcp.2019.09.001.](https://doi.org/10.1016/j.rcp.2019.09.001)
⋆ Please cite this article as: Cassiani-Miranda CA, Cuadros-Cruz AK, Torres-Pinzón H, Scoppetta O, Pinzón-Tarrazona JH, López-Fuentes
WY, et al. Validez del Cuestionario de salud del paciente-9 (PHQ-9) para cribado de depresión en adultos usuarios de Atención Primaria

en Bucaramanga, Colombia. Rev Colomb Psiquiat. 2021;50:11–21.

∗ _Corresponding_ _author._
E-mail address: [ca.cassiani@mail.udes.edu.co](mailto:ca.cassiani@mail.udes.edu.co) (C.A. Cassiani-Miranda).

[https://doi.org/10.1016/j.rcpeng.2019.09.002](https://doi.org/10.1016/j.rcpeng.2019.09.002)
2530-3120/© 2019 Asociaci´on Colombiana de Psiquiatr´ıa. Published by Elsevier Espa ˜na, S.L.U. All rights reserved.


-----

(95% CI: 3.61–6.74); LR− 0.12 (95% CI: 0.005–0.270). In sum, the Colombian version of PHQ-9

is a valid and reliable instrument for depression screening in primary care in Bucaramanga,


with


a cut-off point ≥7.

© 2019 Asociaci´on Colombiana de Psiquiatr´ıa. Published by Elsevier Espa ˜na, S.L.U. All


_Palabras_ _clave:_

PHQ-9

Reproducibilidad de los

resultados

Cribado

Depresión

Atención primaria de salud

Colombia

##### Introduction


rights reserved.

##### Validez del Cuestionario de salud del paciente-9 (PHQ-9) para cribado de depresión en adultos usuarios de Atención Primaria en Bucaramanga,
 Colombia

 r e s u m e n

El Cuestionario de salud del paciente-9 (PHQ-9) es uno de los instrumentos de autoinforme

más utilizado en Atención Primaria (AP). No existe validez de criterio del PHQ-9 en Colombia.


El

Se

de

AP


objetivo fue realizar la validez de criterio del PHQ-9 como instrumento de cribado en AP.

realizó un estudio trasversal de validez de criterio de una escala usando como criterio

referencia la minientrevista neuropsiquiátrica (MINI) en usuarios adultos de centros de


de ambos sexos. Se calcularon la consistencia interna y la validez convergente y de


criterio del PHQ-9 mediante el análisis de las características operativas del receptor (COR) y

el área bajo la curva (ABC). Participaron 243 pacientes, 184 (75,7%) fueron de sexo femenino.


El promedio de edad fue 34,05 (mediana 31 y DE = 12,47). El � de Cronbach fue 0,80 y � de


McDonald, 0,81. La rho de Spearman fue 0,64 para HADS-D (p < 0,010) y 0,70 para PHQ-2


(p < 0,010). El ABC fue 0,92 (IC del 95%, 0,880-0,963). El punto de corte óptimo del PHQ-9 fue


≥ 7: sensibilidad de 90,38 (IC del 95%: 81,41-99,36); especificidad de 81,68 (IC del 95%: 75,93
87,42); el VPP 57,32 (IC del 95%: 46,00-68,63); el VPN 96,89 (IC del 95%: 93,90-99,88); índice


de Youden 0,72 (IC del 95%: 0,62-0,82; LR+ 4,93 (IC del 95%: 3,61-6,74); LR– 0,12 (IC del 95%:


0,005-0,270). En conclusión, la versión colombiana del PHQ-9 es un instrumento válido y

confiable para el cribado de depresión en AP de Bucaramanga, con un punto de corte ≥ 7.


©


2019 Asociaci´on Colombiana de Psiquiatr´ıa. Publicado por Elsevier Espa ˜na, S.L.U.

Todos los derechos reservados.


Depression is a major public health problem worldwide[1] and
has a significant impact on quality of life,[2] high morbidity levels,[3] reduced life expectancy[4] and excess mortality.[5]

The lifetime prevalence of major depressive disorder (MDE)
is 11.2%.[6] Prevalences tend to be higher in low and middle
income countries such as Pakistan, where depression prevalences of 45.9% have been reported.[7] In primary care (PC), the
prevalence of MDE varies significantly in a range from 4.5% to
47.8%.[8]

In the 2015 Colombian National Mental Health Survey, the
prevalence of major depression in the general population was
5.4 (95% CI: 4.6–6.4), 2.3 (95% CI: 1.8–2.9) and 0.8 (95% CI: 0.5–1.3)
for lifetime, the last year and the last month, respectively.[9] In
Bucaramanga, the prevalence of clinically significant depressive symptoms (CSDS) was 22.3% (95% CI: 20.0–24.6) and 11.2%

for major depressive disorder (MDD) (95% CI: 9.7–12.9%).[10]

A later population study in adults living in Bucaramanga
(N = 266), using the Structured Clinical Interview for DSM-IV
Axis I Disorders (SCID-I), reported a prevalence of 16.5% (95%
CI: 12.3–21.6),[11] which confirms the high prevalence of depression in this region.


In spite of its high burden, chronicity and recurrent nature,
depression is underdiagnosed in PC, as approximately 50% of

patients who present depression will not be detected.[12] This
diagnostic gulf could be explained by the fact that more than
75% of patients with depression initially consult a family or PC
physician with little training in the identification of depressive
disorders,[13] time constraints in busy PC environments[14] and
the lack of validated screening tools in low and middle income
countries.[15]

Because of the above, programmes have been developed
to recognise depression,[16,17] which recommend standardised
tools. A number of tools exist to identify cases of depression;
however, their benefits have not been fully determined and the
literature reveals contradictory results.[18] A recent systematic
review suggests that of the screening tools, only the Patient
Health Questionnaire-9 (PHQ-9) attains the optimum accuracy level for depression.[19] The PHQ-9 is an adjectival scale
derived from the Primary Care Evaluation of Mental Disorders
(PRIME-MD) to assess depressive symptoms using the DSM-IV

criteria.[20] The PHQ-9 is shorter than most of the depression
screening scales[21,22] and is considered the best screening tool
for depression in PC due to its accuracy, brevity, being in the
public domain and multipurpose, and ease of administration,
scoring and interpretation.[19,23] The PHQ-9 has been translated
into more than 20 languages and used in many countries and


-----

contexts.[24] In PC, the sensitivity of the PHQ-9 was between 0.71
and 0.84 (mean 0.77) and its specificity was between 0.90 and
0.97 (mean 0.94),[25] confirming its adequate psychometric performance in PC, albeit with some variations in the cut-off point
(COP) and psychometric parameters that can be explained by
the influence of cultural aspects in the response pattern.[23] Its
broad use is also supported by the findings of Williams et al.,
who concluded, in an analysis of more than 38 studies with
more than 32,000 PC patients, that the PHQ-9 was equal or
superior to other measures of depression.[22] In addition, the

DSM-5 MDD working group and the NICE guidelines consider
the PHQ-9 the preferred measure to assess the presence of the
depression and quantify its severity.[21,22,26]

The PHQ-9 has been evaluated in Colombia in university
students[27]: however, it was not compared to a gold standard.
The PHQ-9 criteria therefore need to be validated in PC in

Colombia against a gold standard, in particular due to the

opportunity PC services represent in the early detection of
depression.[28] As a result, this study’s objective was to assess
the validity of the PHQ-9 criteria, comparing it with the MiniInternational Neuropsychiatric Interview (MINI) for screening

for depressive symptoms in adult PC users in the Bucaramanga metropolitan area.

##### Materials and methods

**_Design_**

This study was designed and analysed based on the recommendations of the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) declaration.[29] An analytical observational
study of the validity of a scale’s criteria was conducted using
reference criteria.

**_Participants_**


Local PC users of both genders, aged 18–65 years were
included. The PC centres belong to the Instituto de Salud de
Bucaramanga [Bucaramanga Health institute] (ISABU), a State
social enterprise that coordinates primary health care services
in the Bucaramanga metropolitan area.
Subjects with psychoactive symptoms, cognitive decline,
delirium or an intellectual disability that might prevent them
from responding to the tools, those under the effects of psychoactive substances, with functional changes in vision or
hearing that might prevent them from understanding the content of the survey, and those who did not understand Spanish

were excluded. The sample size was calculated to evaluate the
hypothesis regarding the characteristics of a diagnostic test[30]:


the health centres until a maximum number of subjects above
214 had been surveyed.

**_Procedures_**

The study was approved the ethics committee of ISABU and
the Universidad de Santander [University of Santander], taking into account the current international[31] and national
norms[32] for research with human subjects.
The PHQ-9 was translated following the recommendations

for adaptation of self-reporting tests.[33] A direct translation
from the original scale was performed by two independent
certified bilingual translators; discrepancies between the two
translations were discussed, then a backtranslation was done
into English, which was reviewed by the research team to
assess its closeness to the original scale. The translated scale
was then reviewed by 10 psychiatrists with research expertise or clinical experience to verify whether the items were
consistent with the construct of depression, who also commented on the comprehension and wording of the items. Ten
people from the general population with a history of depression also gave their opinions on the comprehension of the
questions. The research group analysed and incorporated the
patients’ and experts’ observations to obtain the new Colombian version (Fig. 1). With the new version of the scale, a pilot
test was conducted with 21 subjects with characteristics similar to the study subjects but in other centres. They answered
the questions without difficulties and no adjustments to the
grammatical structure were needed.
The research team was trained in the structured psychiatric interview (MINI) and hetero-administration of the PHQ-9.
The people responsible for administering the scales and structure interviews were professionals with clinical experience
(four psychologists, two general practice residents and one

psychiatrist) who received eight hours of training by the lead

author, with theoretical and practical sessions, role playing, and observation of pilot interviews with feedback. The
study participants were contacted in the waiting room as they
arrived for outpatient appointments with a general practitioner for any reason. One member of the research group
explained the nature of the study and gave them the informed
consent form. The screening scales were read by trained
members of the research team. After completing the PHQ-9,
each participant was assessed on the same day in another
consulting room by a different trained member of the team
(psychologist or psychiatrist) who did not know their PHQ-9

result, to administer the MINI depression module. The questionnaires were reviewed by two independent reviewers and
saved in a form generated in Excel.



[�1(1 − �)]��Z1−B�

ı[2]


#### �2

[�2(1 − �2)]


N =


#### � �
Z1−˛/2


where �1 is the sensitivity of the standard (0.96) and �2 is the
anticipated sensitivity of the PHQ-9 (0.88); _Z1−˛/2 was_ set at
1.96 and _Z1-B at_ 1.28; ı was set at 0.08 (�1 − �2). The result was
214 P ti i t l t d ti l th tt d d


**_Tools_**

_PHQ-9_
The PHQ-9 is a screening scale that measures the presence and
severity of depressive symptoms.[34] The PHQ-9[35] is made up
of the nine symptoms from DSM-IV MDE criterion A.[20] These
nine items are arranged in the form of an adjectival scale that
assesses the presence of the symptom in the last two weeks
(“ t t ll” “ l d ” “ th h lf th d ” d


-----

|Durante las últimas 2 semanas, ¿qué tan a menudo le han afectado alguno de los siguientes problemas? (Use «√ » para indicar su resp uesta)|Para nada|Varios días|Más de la mitad de los días|Casi todos los días|
|---|---|---|---|---|
|1. Poco interés o placer para hacer las cosas|||||
|2. Sentirse triste, deprimido o sin esperanzas|||||
|3. Dificultad para conciliar o mantener el sueño, o dormir demasiado|||||
|4. Sentirse cansado o tener poca energía|||||
|5. Mal apetito o comer en exceso|||||
|6. Sentirse mal sobre sí mismo (o que es un fracaso o se ha decepcionado a usted o a su familia)|||||
|7. Dificultad para concentrarse en actividades, como leer el periódico o ver televisión|||||
|8. Moverse o hablar tan despacio que otras personas pueden haberlo notado. O lo contrario, sentirse tan nervioso e inquieto que ha estado moviéndose más de lo usual|||||
|9. Pensamientos de que estaría mejor muerto o de lastimarse austed mismo de alguna manera|||||


Fig. 1 – Patient Health Questionnaire (PHQ-9), version for Primary Care, Bucaramanga, Colombia.


“nearly every day”), scored from 0 to 3 to give a score between
0 and 27.[36]

It can be self- or hetero-administered and is used both
algorithmically to make a probable diagnosis of MDE or as
a continuous measure of scores from 0 to 27 with cut-off
points (COP) at 5, 10, 15 and 20 representing levels of depressive symptoms, i.e. mild, moderate, moderately severe and
severe.[34] The scores can also be used dichotomously based on
a COP to classify subjects with or without CSDS.[37] According
to Kroenke et al., the psychometric characteristics of the PHQ9 have a sensitivity of 88% and a specificity of 88%, adequate
internal consistency (Cronbach’s ˛ of 0.86–0.89), a test–retest
score of 0.84, a concordance between self-administered and
evaluator-administered tests of 84% and an area under the
curve (AUC) of 0.95.[34] In this study a COP of 8 or more was
used to identify cases of CSDS, based on the meta-analysis by
Manea et al.[23] and the study by Rancans et al. in PC.[38]

_Mini-International_ _Neuropsychiatric_ _Interview_
The MINI is a brief structured diagnostic interview that
explores the diagnostic categories of the DSM-IV and the ICD10.[39] Its original version was developed by Sheehan et al.[39] and
Lecrubier et al.[40] in the United States and France. It contains
130 questions organised into modules that assess 16 disorders from axis i of the DSM-IV and one personality disorder.
The original version in English has a sensitivity range between
0 46 d 0 94 d ifi it b t 0 72 d 0 97 [39 40]


excellent inter-rater (kappa 0.70) and test–retest reliability, and
moderate validity of criteria compared to the Composite International Diagnostic Interview (CIDI) and the SCID-P.[39,40] The
MINI quickly gained international acceptance,[41–43] has translated versions in 43 languages[39] and its reliability and validity
have been explored in its Italian,[44] Japanese,[45] Norwegian,[46]

Moroccan[47] and Portuguese[48] versions. The average administration time is 18.7 ± 11.6 min, with a mean of 15 min.[39]

Together with the CIDI and the SCID-I, the MINI is considered
a globally accepted gold standard for the diagnosis of mental
disorders in clinical and research settings.[49]

_Hospital_ _Anxiety_ _and_ _Depression_ _Scale_

The Hospital Anxiety and Depression Scale (HADS) was
designed by Zigmond and Snaith in 1983[50] to detect mood disorders, especially those associated with somatic symptoms. It
consists of 14 items, with an anxiety subscale (odd items) and
a depression subscale (even items). Each item is graded on a
four-point frequency scale from 0 to 3. The HADS has been
translated into most European languages, Arabic, Hebrew,
Urdu, Japanese and Chinese[51] and its reliability and validity
has been demonstrated in numerous studies.[52] In Colombia,
it was validated in cancer patients, finding adequate internal
consistency (Cronbach’s ˛ of 0.85), a COP of 8 for the anxiety
subscale and 9 for the depression subscale.[53] These psychot i ti fi d i l ti l l


-----

(n = 1500) in several cities in Colombia.[54] In this work, the version adapted by Rico et al. was used.[53]

_Patient_ _Health_ _Questionnaire-2_
The Patient Health Questionnaire-2 (PHQ-2) consists of the
first two items of the PHQ-9, which are necessary to suspect
the presence of depression according to the DSM-IV criteria.[55]

The scoring system is the same as for the PHQ-9 and scores
range from 0 to 6. A COP of 3 is optimal for screening, but a
recent meta-analysis suggests that a COP of 2 may increase
its sensitivity.[56] Patients who score positive for CSDS should
be evaluated with the PHQ-9 to determine whether they meet
the MDE criteria.[57] Its clinical utility stems from the fact that
it reduces the time taken in normal PC consultations, which
are usually busy.[58] The PHQ-2 has been found to have psychometric performance comparable to the PHQ-9, with good
reliability, validity and sensitivity to change.[56] In this work, a
COP of 2 or above was used to identify patients with CSDS.[59]

**_Statistical_** **_analysis_**

The data were analysed in SPSS version 20.0,[60] carefully
verified and reviewed twice. A descriptive analysis of the qualitative and quantitative variables was performed. Cronbach’s ˛
and McDonald’s ω coefficients were calculated to assess internal consistency; for concurrent validity, Spearman or Pearson
correlations were estimated depending on the distribution
of the variables. To assess the accuracy of the PHQ-9 as a
screening tool compared to the MINI, the receiver operating
characteristics (ROC) and AUC were analysed. The optimum
COP for the PHQ-9 was determined taking into account validity
indices: sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), positive and negative likeli
hood ratios (LR), Youden’s index and ROC curve/AUC analysis.

##### Results

**_Participant_** **_characteristics_**

Three hundred and eighty-four users were contacted, of
whom 95 did not agree to participate. Of the surveys conducted, 46 were discarded due to missing and inconsistent
data; the analysis therefore included 243 participants, of
whom 184 (75.7%) were female. The average age was 34.05
years with a standard deviation (SD) of 12.47 years. For male
participants the average age was 33.59 years with a SD of
12.89 years, while for female participants the average was
34.20 years with a SD of 12.37 years. The sociodemographic
characteristics of the sample can be seen in Table 1.
The prevalence of CSDS was 27.2% according to the results
of the PHQ-9 and 21.8% according to the MINI structured interview.

**_Internal_** **_consistency_**


Table 1 – Description of the sociodemographic
characteristics of patients with or without minor
depressive symptoms receiving healthcare at Primary
Care centres.

|Care centres.|Col2|
|---|---|
|Variables|No. %|
|Gender Male Female Areaoforigin Urban Rural Maritalstatus Single Married Cohabiting Divorced Widowed Education Primary,notcompleted Primary,completed Secondary,notcompleted Secondary,completed Vocational,notcompleted Vocational,completed Technological,completed University,notcompleted University,completed Socio-economicstratum Stratum1 Stratum2 Stratum3 Stratum4 Stratum5|59 24.30% 184 75.72 210 86.42 33 13.58 98 40.33 53 21.88 83 34.16 5 2.06 4 1.65 14 5.75 60 24.69 36 14.81 88 36.21 18 7.41 1 0.41 3 1.23 3 1.23 20 8.23 103 42.39 84 34.57 47 19.34 6 2.47 3 1.23|


Table 2 – Description of the internal consistency of the
PHQ-9 Colombian version: Cronbach’s **˛** and McDonald’s
**ω** by item.

PHQ-9 questions Cronbach’s ˛ McDonald’s ω


Q1 0.774 0.780
Q2 0.767 0.772

Q3 0.795 0.800
Q4 0.776 0.784

Q5 0.792 0.798

Q6 0.778 0.782
Q7 0.788 0.794

Q8 0.798 0.805
Q9 0.799 0.802


A Cronbach’s ˛ coefficient of 0.80 and an ω coefficient of 0.81
were obtained. The overall internal consistency of the scale if

each item is eliminated is shown in Table 2.


**_Convergent_** **_validity_**

The Kolmogorov–Smirnov test was used to establish the normality of the variables, for the purpose of deciding the type
of test to use for the concurrent validity analysis of the
PHQ-9 against the PHQ-2 and the HADS depression subscale
(HADS-D). These variables were not found to have a normal
distribution, to Spearman’s Rho was used. The Spearman’s
Rho was 0.646 for the HADS-D (P < 0.010) and 0.701 for the
PHQ-2 (P < 0.010).


-----

Table 3 – Description of the various cut-off points for the PHQ-9 Colombian version and validity coefficients.


Cut-off point Sensitivity Specificity Youden’s index % correctly classified PPV NPV LR+ LR−

≥3 0.98 0.43 0.42 55.14 0.25 0.99 1.73 0.04
≥4 0.96 0.58 0.54 65.84 0.30 0.99 2.27 0.07

≥5 0.96 0.71 0.67 76.54 0.39 0.99 3.34 0.05
≥6 0.94 0.77 0.71 80.66 0.44 0.99 4.09 0.07
≥7[a] 0.90[a] 0.82[a] 0.72[a] 83.54[a] 0.48[a] 0.98[a] 4.93[a] 0.12[a]

≥8 0.83 0.88 0.71 86.83 0.57 0.96 6.87 0.20
≥9 0.75 0.91 0.66 87.24 0.60 0.95 7.96 0.28

≥10 0.67 0.93 0.60 87.24 0.64 0.94 9.18 0.35

≥11 0.60 0.94 0.54 86.83 0.66 0.92 10.35 0.43
≥12 0.56 0.97 0.53 88.07 0.77 0.92 17.75 0.46

≥13 0.46 0.97 0.43 86.01 0.74 0.90 14.69 0.56
≥14 0.31 0.99 0.30 84.36 0.85 0.88 29.38 0.70

≥15 0.27 0.99 0.26 83.95 0.91 0.88 51.42 0.73

a Psychometric indices associated with the optimum cut-off point of ≥7.


ROC curve


1.0

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1


0.0

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

1-Specificity

Fig. 2 – Receptor operating characteristics (ROC) of the
PHQ-9 Colombian version compared with the MINI as a
reference standard for depression (N = 146).


**_Criterion_** **_validity_**

The ROC curve (Fig. 2) and accuracy indices for the PHQ-9 produced the results shown in Table 3. The AUC was 0.92 (95% CI:
0.88–0.963).
The optimum COP was a PHQ-9 score ≥7 (sensitivity 90.38

[95% CI: 81.41–99.36]; specificity 81.68 [95% CI: 75.93–87.42]; PPV
57.32 [95% CI: 46.00–68.63]; NPV 96.89 [95% CI: 93.90–99.88];
Youden’s index 0.72 [95% CI: 0.62–0.82]; LR+ 4.93 [95% CI:

3.61–6.74]; LR− 0.12 [95% CI: 0.005–0.270]).


##### Discussion

To the best of our knowledge, this is the first study on PHQ-9
criterion validity in PC in Colombia. The prevalence of MDE
in this study was 21.8%. The Colombian version of the PHQ-9
demonstrated excellent diagnostic performance as a depression screening tool, as can be seen from the ROC curve and
AUC. The PHQ-9 also demonstrated an adequate balance of
iti it d ifi it t th COP f 7 h d


with the MINI as a reference standard, establishing the PHQ-9’s
adequate criterion validity. The comparison of PHQ-9 scores
against those from the HADS-D and the ˛ and ω coefficients
demonstrated good convergent validity and adequate internal

consistency.
The percentage of subjects classified as having CSDS based

on the PHQ-9 with the pre-established COP was 27.2% (95%
CI: 26.3–28.9), higher than the prevalence of 22.3% (95% CI:
20.0–24.6) found in Bucaramanga using the Zung Self-rating
Depression Scale.[10] This difference can be explained by the
poor diagnostic performance of the Zung scale in the Colombian population.[61] With regard to the prevalence of MDE based
on the MINI, in this sample it was 21.8% (95% CI: 20.8–23.5),
which is within the expected range based on a meta-analysis
of 41 studies in PC with an adjusted global prevalence of
19.5% (95% CI: 15.7–23.7).[62] However, the prevalence of MDE in
this study is a little higher than the 16.5% (95% CI: 12.3–21.6)
reported in previous studies in the general population in
Bucaramanga,[11] which can be explained by the fact that this
study was conducted in people attending PC centres, where
the prevalence of depression is higher than in the general
population[63] and by the large proportion of women.[64]

Cronbach’s ˛ coefficient was 0.80 and McDonald’s ω coefficient was 0.81, indicating good internal consistency.[65,66] For a
self-reporting tool to be reliable, Cronbach’s ˛ and McDonald’s
ω need to be at least 0.70.[67] The internal consistency found in
this study is in keeping with a previous study in Colombia[37]

and with others conducted in different languages, whose coefficients ranged from 0.79 to 0.89.[68,70,71]

Previous studies have demonstrated that the PHQ-9 has
adequate concurrent validity with various measured, including the Hamilton Depression Rating Scale (HAM-D), short
health assessment forms and even the PHQ-2.[72] In our study,
total PHQ-9 scores showed a statistically significant positive
correlation with HADS-D and PHQ-2 scores (Spearman’s Rho of
0.64 [P < 0.01] for HAM-D and 0.70 [P < 0.01] for PHQ-2), in keeping with previous studies in which the Pearson’s coefficients
for the PHQ-9 with the HAM-D and the Beck Depression Inventory (BDI) were 0.52 and 0.76, respectively.[68,73–75] Meanwhile,

a study of patients with Parkinson’s disease showed that
the PHQ-9 correlated positively with the Self-rating Depression Scale and the 15-item Geriatric Depression Scale, with


-----

a Spearman’s coefficient of 0.63 in both cases.[76] The correlation coefficients found in this study confirm the convergent
validity of the PHQ-9, with Spearman’s correlation coefficients
between 0.60 and 0.80 indicating a good or considerable positive correlation.[77]

With regard to the COP, various studies have recommended
a COP of 10 in the PHQ-9 for the identification of MDE.[34] For
example, in a study of PC users in China, an optimum COP
of 10 produced a sensitivity of 0.87 and a specificity of 0.8.[69]

However, a recent meta-analysis of 18 studies demonstrated
that the optimum COP of the PHQ-9 could range from 8 to 11,
depending on the population studied; nevertheless, the balance of sensitivity and specificity is maintained for a COP of

7 (5 of the 18 studies included).[23] In our study, the COP of 7

appears to have given the optimum balance between sensitivity and specificity, which was confirmed with an additional

measure of accuracy: Youden’s index,[78] defined as the max
imum vertical distance between the ROC curve and the 45
degree line, as an indicator of how far the curve is from an
uninformative test.[79] Youden’s index is a function of sensitivity (Se) and specificity (Sp); it is calculated as (Se + Sp-1)[80]

and should be considered alongside the ROC curve as they are
usually related.[81] The range is 0–100 when converted into a
percentage. Values >50% are generally considered acceptable
for diagnostic accuracy.[82]

The values associated with the COP in our study are con
sistent with a study in older adults in PC, in whom PHQ-9

criterion validity was assessed by administering the MINI, in
which an optimum COP ≥ 7 (sensitivity 0.92; specificity 0.78)
demonstrated the best psychometric characteristics.[83] Nevertheless, this COP of 7 is lower than that found in most
studies with the PHQ-9 in other populations. The cultural and
demographic characteristics of the samples may be the reason for this difference.[84] Stigma is an important aspect that
can also influence people’s response pattern to depression
screening scales in our population, causing shame in people with mental illnesses, which limits the identification of
psychopathological phenomena.[85,86] It is worth noting that

PHQ-9 COPs tend to be lower in middle and low income
countries[87–89] compared with high income countries.[75,90,91]

However, there are no studies looking at this phenomenon.
This difference in optimum COP highlights the importance
of validating screening tools in different social and cultural
contexts.[92]

For a COP of ≥7, the sensitivity and specificity of the PHQ-9
in this sample were 90% and 83%, respectively. These findings are consistent with the study by Wang et al., in which the
COP of ≥7 allowed an adequate balance between sensitivity
and specificity (sensitivity 85%; specificity 86%).[93] The accuracy indices in our study are therefore considered appropriate,
as the screening tool is considered good when its sensitivity is
between 79% and 97% and its specificity is between 63% and
86%.[94] Wittkampf et al. systematically reviewed the psychometric properties of the PHQ-9 and found a sensitivity of 77%
(71–84%) and specificity of 94% (90–97%), including studies in

subgroups with a high prevalence of depression, such as PC

users.[25]

The LR+ and LR− of the PHQ-9 in our sample, for a COP
of ≥7, were 4.93 and 0.12, respectively. This means that, in a


if five times more common in a patient with depression than
in one without depression, while a subject with a negative
result would have a likelihood of having depression of less
than 2%.[95] These results are comparable with those obtained
in the Chinese version of the PHQ-9, which with a COP of ≥7,
had an LR+ and LR- of 5.99 and 0.17, respectively.[93]

The AUC of this Colombian version of the PHQ-9 for PC was
0.92, which indicates a high degree of accuracy[96] and is consistent with previous studies in PC and other populations.[69,71,93]

This study’s main strengths include the use of a clinical
reference criterion to assess the PHQ-9 validity criterion, the
adequate participant response rate (75.3%), adequate training of interviewers, adherence to the QUADAS-2 guidelines[29]

and the execution of a rigorous analysis plan. In addition, the
PHQ-9 was translated in accordance with the standardised
guidelines for transcultural adaptation of scales. The linguistic
adaptation was supported by a group of experts, guaranteeing

appropriate content validity.

This study has several limitations. Firstly, our study was
conducted in a PC context, therefore the results cannot be
generalised to the general population, whose characteristics would produce a different response pattern.[84] Secondly,
the study was limited to adults. There is growing evi
dence that adolescents are particularly affected by depressive
disorders,[97] so future studies in Colombia would need to
assess the psychometric performance of the PHQ-9 in this
population. Thirdly, this was a cross-sectional study, and as

a consequence there will be a need, in the future, to design
longitudinal studies to establish the sensitivity to change of
the PHQ-9 in the Colombian population, as works exist that
have used in to assess response to treatment of depression.[98]

Fourthly, the fact that the sample was predominantly female
(75%) could affect the estimates of accuracy indices, as the
prevalence of depression is higher in women than in men,
giving a higher number of positive cases of depression.[99] And
fifthly, one relative weakness in the sample size, which was
calculated following the recommendations of Sanchez et al.
for comparing the sensitivity of a screening test with a reference standard.[30] However, other authors, such as Buderer[100]

and Obuchowski[101] demand larger samples. On the other
hand, following Bean’s criteria for comparing the sensitivity
or specificity of two diagnostic tests, sample sizes similar to
ours are obtained.[102]

In keeping with global results, the Colombian version of
the PHQ-9 for PC has excellent psychometric performance
as a screening test, which guarantees that it can be used
in contexts with few resources and with weaknesses in the
healthcare system, where the availability of psychiatrists is
limited.[103] Among the strategies to limit the burden of mental health disorders in low and middle income countries is
integration of mental health in PC.[104] One of the major barriers to achieving this goal is the lack of easy-to-administer
and validated screening tools to detect depression. The validation of instruments such as the PHQ-9 in these contexts
can help to solve this problem.[105] It is known that just screening for depression is insufficient to mitigate the growing care

needs for mental health disorders in low and middle income
countries; nevertheless, given that depression contributes significantly to the burden of disease, having validated screening
t l i th fi t t t d l i thi bl 106 I


-----

some low income countries, there are cost-effective depression intervention programmes, in which screening tools can
be used to identify appropriate participants.[107] One of the
main components of effective mental health interventions in
PC is monitoring depressive symptoms using simple, brief and
easy-to-administer questionnaire such as the PHQ-9.[108]

With the validation of this version of the PHQ-9,
researchers in Colombia now have valid and reliable psychometric information about depression screening in PC, which
will enable the PHQ-9 to be used in studies where it is necessary to identify depressive symptoms with an appropriate
COP.
In conclusion, the results of this study indicate that the

Colombian version of the PHQ-9 is a valid and reliable tool
for screening for depression in a PC context in Bucaramanga,
with a COP of 7 or above. The psychometric properties of this
version of the PHQ-9 will need to be evaluated in different

populations and other regions of the country. Future studies

in Colombia should assess the PHQ-9’s sensitivity to change.

##### Funding


This work was funded by the faculty of medicine of the Universidad de Santander (UDES) and the Instituto de Salud de

Bucaramanga (ISABU). Project code: PIFE0118020041816EJ.

##### Authors’ contribution


Carlos Arturo Cassiani-Miranda: design, scale adjustment,
training of survey-takers and interviewer, collection of information, statistical analysis, digitisation, drafting and revision
of the article.
Angy Karina Cuadros-Cruz: design, scale adjustment, collection of information and drafting of the article.
Harold Torres Pinzón: design, scale adjustment, statistical
analysis, digitisation, drafting and revision of the article.
Orlando Scoppetta: scale adjustment, statistical analysis,
drafting and revision of the article.

Jhon Henrry Pinzón-Tarrazona: collection of information,
digitisation and drafting of the article.
Wendy Yulieth López-Fuentes: collection of information,
digitisation and drafting of the article.
Andrea Paez: collection of information and drafting of the
article.
Diego Fernando Cabanzo-Arenas: digitisation, drafting and
revision of the article.
Sergio Ribero-Marulanda: collection of information, drafting and revision of the article.
Elkin René Llanes-Amaya: collection of information and
drafting of the article.

##### Conflicts of interest

Th th h fli t f i t t t d l


##### Acknowledgements

To the expert panel for their contributions to the validation
of appearance and content: Astrid I. Arrieta, Jaider A. Barros, Adalberto Campo-Arias, Mauricio Casta ˜no, Jenny García,
Luis A. Montenegro, Jorge A. Ni ˜no, Heidi C. Oviedo, Andrés M.
Rangel, Jorge J. Téllez-Vargas.

##### r e f e r e n c e s

1. [Steel](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Ford](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [JA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Newton](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [JN,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Davis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [ACJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Vos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Naghavi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545)
[et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Changes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [countries](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [UK](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [150](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545)

[English](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Local](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Authority](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [areas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [1990–2016:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545)

[analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Global](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Burden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Disease](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Study](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [2016.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545) [Lancet.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545)

[2018;392:1647–61.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0545)
2. [Yang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [D,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [Hur](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [JW,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [Kwak](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [YB,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [Choi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [SW.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [review](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550)
[meta-analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [applicability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [web-based](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [interventions](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550)

[for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [individuals](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [quality](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [life](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550)

[impairment.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [Investig.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550) [2018;15:759–66.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0550)

3. [Van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Eck](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [der](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Sluijs](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [JF,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Castelijns](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Eijsbroek](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [V,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Rijnders](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)
[CAT,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Marwijk](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [HWJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [der](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Feltz-Cornelis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [CM.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Illness](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)

[burden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [physical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [outcomes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [associated](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [collaborative](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)

[care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [patients](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [comorbid](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [disorder](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)

[chronic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [medical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [conditions:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [review](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)
[meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555) [2018;50:1–14.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0555)

4. [Laursen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [TM,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Musliner](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [KL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Benros](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [ME,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Vestergaard](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560)
[Munk-Olsen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [T.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Mortality](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [life](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [expectancy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [persons](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560)

[severe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [unipolar](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [depression.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560) [2016;193:203–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0560)

5. [Brandão](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [D,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Fontenelle](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [LF,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [da](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Silva](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [SA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Menezes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [PRP-VM.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565)
[Depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [excess](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [mortality](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [elderly](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [living](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [low-](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [middle-income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [countries:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [review](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565)

[meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Int.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Geriatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565) [2019;34:22–30.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0565)
6. [Kessler](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [RC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Sampson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [NA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Berglund](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Gruber](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [MJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570)
[Al-Hamzawi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Andrade](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Anxious](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [non-anxious](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570)

[major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [disorder](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [World](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Organization](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570)

[World](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Surveys.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Epidemiol](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Psychiatr](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570) [Sci.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570)

[2015;24:210–26.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0570)
7. [Muhammad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [Gadit](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [AA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [Mugford](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [G.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [Prevalence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575)
[among](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [households](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [three](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [capital](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [cities](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [Pakistan:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [need](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575)
[to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [revise](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [policy.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [PLoS](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [ONE.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575) [2007;2:1–5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0575)

8. [Wang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Wu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [X,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Lai](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [W,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Long](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Zhang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [X,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Li](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [W,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Prevalence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580)
[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [symptoms](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [among](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [outpatients:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580)

[a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [review](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [BMJ](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580) [Open.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580)

[2017;7:1–14.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0580)
9. [Gómez-Restrepo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Bohórquez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Tamayo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Martínez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585)
[Rondón](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Bautista](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Rengifo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Trastornos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [depresivos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585)

[y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [ansiedad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [factores](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [asociados](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [población](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585)

[adolescentes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [colombianos,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Encuesta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Nacional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Salud](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585)

[Mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [2015.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Colomb](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Psiquiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [2016;45](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [Suppl.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585) [1:50–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0585)

10. [Rueda-Sánchez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Díaz-Martínez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [LA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Rueda-Jaimes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [GE.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590)
[Prevalencia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [trastorno](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [depresivo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [mayor](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [factores](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590)

[asociados:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [un](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [estudio](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [poblacional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Bucaramanga](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590)

[(Colombia).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Colomb](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [Psiquiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590) [2008;37:159–68.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0590)

11. [Cadena](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Díaz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Rueda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Hernández](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Campo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595)
[Prevalencia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [actual](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [trastorno](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [depresivo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [mayor](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595)

[población](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Bucaramanga,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Colombia.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Fac](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Nac](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [Salud](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595)

[Pública.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595) [2010;28:36–41.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0595)

12. [Mitchell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [AJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [Rao](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [Vaze](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [Can](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [general](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [practitioners](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [identify](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600)
[people](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [distress](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [mild](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [depression?](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [meta-analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600)

[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [accuracy.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600) [2011;130:26–36.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0600)

13. [Carey](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Yoong](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [SL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Grady](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Bryant](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Jayakody](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605)
[Sanson-Fisher](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Unassisted](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [detection](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [by](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605)

[GPs:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [who](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [is](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [most](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [likely](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [be](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [misclassified?](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Fam.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605) [Pract.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605)

[2015;32:282 7](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0605)


-----

14. [Mitchell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [AJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [Rao](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [Vaze](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [comparison](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610)
[clinicians’](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [ability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [identify](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610)

[meta-analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [meta-regression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [predictors.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610)

[Pract.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610) [2011;61:72–80.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0610)

15. [Ali](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [GC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [Ryan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [Silva](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [MJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [Validated](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [tools](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615)
[common](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [disorders](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [low](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [middle](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615)

[countries:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [review.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [PLOS](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [ONE.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615) [2016;11:1–14.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0615)

16. [Paykel](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [ES,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Tylee](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Wright](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Priest](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [RG,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Rix](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Hart](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [D.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620)
[defeat](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [campaign:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [public](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [arena.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620)

[Am.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [1997;154](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620) [Suppl.:59–66.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0620)
17. [Mitchell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Dwyer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Hagan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Mathers](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [N.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Impact](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [QOF](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625)
[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [NICE](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [guideline](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [management](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625)

[depression:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [qualitative](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [study.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625) [Pract.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625)

[2011;61:279–89.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0625)
18. [Gilbody](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [Sheldon](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [House](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [case-finding](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630)
[instruments](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [depression:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630) [CMAJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630)

[2008;178:997–1003.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0630)
19. [Pettersson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Boström](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [KB,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Gustavsson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Ekselius](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [L.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Which](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635)
[instruments](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [support](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [have](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635)

[sufficient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [accuracy?](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [review.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Nord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635)

[2015;69:497–508.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0635)
20. [Kocalevent](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [RD,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Hinz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Brähler](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [E.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Standardization](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640)
[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [screener](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [(PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640)

[the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [general](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [population.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640) [2013;35:551–5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0640)

21. [Sung](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [SC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Low](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [CCH,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Fung](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [DSS,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Chan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [YH.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [minor](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [multiethnic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [sample](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Asian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)
[primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [patients:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [comparison](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [nine-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)

[Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [(PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [16-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Quick](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)

[Inventory](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Symptomatology](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [–](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Self-Report](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)

[(QIDS-SR16).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Asia-Pacific](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645) [2013;5:249–58.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0645)
22. [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [JW,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Pignone](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Ramirez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Perez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Stellato](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [C.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650)
[Identifying](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [literature](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650)

[synthesis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [case-finding](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [instruments.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650)

[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650) [2002;24:225–37.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0650)

23. [Manea](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [Gilbody](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [McMillan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [D.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [Optimal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [cut-off](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [score](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655)
[diagnosing](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655)

[Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [(PHQ-9):](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655) [CMAJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655)

[2012;184:191–6.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0655)
24. [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [K.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [Enhancing](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660)
[screening.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [CMAJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660) [2012;184:281–2.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0660)
25. [Wittkampf](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [KA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Naeije](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Schene](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [AH,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Huyser](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Weert](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [HC.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665)
[Diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [accuracy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [mood](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [module](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665)

[Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Questionnaire:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [review.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665)

[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665) [2007;29:388–95.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0665)

26. [Deneke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [DE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [Schultz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [Fluent](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [TE.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670)
[the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [population.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [Prim.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [Care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670) [2014;41:399–420.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0670)
27. [Cassiani-Miranda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [CA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Scoppetta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [O.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Factorial](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [structure](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675)
[Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [as](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675)

[instrument](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [university](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [students](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Cartagena,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Colombia.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675)

[Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [Res.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675) [2018;269:425–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0675)

28. [Smithson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [Pignone](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [MP.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [adults](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680)
[primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [North](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [Am.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680) [2017;101:807–21.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0680)
29. [Whiting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [PF,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Rutjes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [AW,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Westwood](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [ME,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Mallett](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Deeks](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [JJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685)
[Deeks](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [JJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [QUADAS-2:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [revised](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [tool](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [quality](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685)

[assessment](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [accuracy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [studies.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Ann.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [Intern.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685)

[Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685) [2011;155:529–36.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0685)

30. [Sánchez-Pedraza](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [Echeverry-Raad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [Aspectos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [sobre](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [dise ˜no](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690)
[y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [tama ˜no](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [muestra](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [estudios](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [pruebas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [diagnósticas.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690)

[Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [Fac](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690) [2001;49:175–80.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0690)

31. Asociación Médica Mundial. Declaración de Helsinki de la
AMM. Principios éticos para las investigaciones médicas en

seres humanos; 2015 [Internet]. Available from:

[http://www.wma.net/es/30publications/10policies/b3/](http://www.wma.net/es/30publications/10policies/b3/)

[Accessed 20 February 2019].
32. [Ministerio](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [Salud.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [Resolucion](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [8430](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [1993.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [República](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700)

[Colombia:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [Ministerio](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [Salud;](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [1993.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [p.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700) [1–12.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0700)


33. [Beaton](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [DE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Bombardier](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Guillemin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Ferraz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [MB.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Guidelines](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705)
[for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [process](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [cross-cultural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [adaptation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [self-report](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705)

[measures.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Spine](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [(Phila](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [Pa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [1976).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705) [2000;25:23186–91.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0705)

34. [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [JBW.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [PHQ-9:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710)
[brief](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [severity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [measure.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [Intern.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710)

[2001;16:606–13.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0710)
35. [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [JB.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [Validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715)
[self-report](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [PRIME-MD.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [JAMA.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715) [1999;282:1737–44.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0715)

36. [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [JBW,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Hornyak](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [McMurray](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)
[Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [PRIME-MD](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)
[Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [assessment](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [3000](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [obstetric-gynecologic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)

[patients:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [PRIME-MD](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)

[Obstetrics-Gynecology](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Study.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Am.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Obstet.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720) [Gynecol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)

[2000;183:759–69.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0720)
37. [Cassiani-Miranda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Vargas-Hernández](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Pérez-Anibal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)
[Herazo-Bustos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Hernández-Carrillo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [M.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Confiabilidad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)

[dimensionalidad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [para](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [el](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [cribado](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)

[sintomatología](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [depresiva](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [estudiantes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [ciencias](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)
[salud](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Cartagena,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [2014.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Biomédica.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [2017;37](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725) [Suppl.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)

[1:112–20.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0725)
38. [Rancans](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Trapencieris](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Ivanovs](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Vrublevska](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730)
[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [PHQ-2](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [screen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730)

[nationwide](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [population](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Latvia.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Ann](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [Gen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730)

[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730) [2018;17:1–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0730)

39. [Sheehan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [DV,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Lecrubier](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Sheehan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [KH,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Amorim](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Janavs](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735)

[Weiller](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Mini-International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735)
[Interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [(M.I.N.I.):](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [development](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735)

[structured](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [psychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [DSM-IV](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735)

[ICD-10.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [1998;59](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [Suppl](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735) [20:22–33.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0735)

40. [Lecrubier](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Sheehan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [DV,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Weiller](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Amorim](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Bonora](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [I,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740)
[Sheehan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [KH,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Mini](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740)

[Interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [(MINI).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [short](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [structured](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [interview:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740)

[reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [according](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [CIDI.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Eur](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740)

[1997;12:224–31.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0740)
41. [Balázs](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Lecrubier](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Csiszér](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Koszták](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Bitter](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [I.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Prevalence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745)
[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [comorbidity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [affective](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [disorders](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [persons](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [making](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745)

[suicide](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [attempts](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Hungary:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [importance](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [first](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745)

[depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [episodes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [bipolar](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [II](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [diagnoses.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745)
[Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745) [2003;76:113–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0745)

42. [Juang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [KD,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Wang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [SJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Fuh](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [JL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Lu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [SR,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Su](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [TP.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Comorbidity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750)
[depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [disorders](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [chronic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [daily](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [headache](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [its](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [subtypes.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [Headache.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750) [2000;40:818–23.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0750)

43. [Pinninti](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [NR,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Madison](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Musser](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Rissmiller](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [D.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [MINI](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755)
[International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Schedule:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755)

[patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [acceptance.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Eur](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755) [2003;18:361364.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0755)

44. [Rossi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Alberio](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Porta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Sandri](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Tansella](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Amaddeo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [F.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760)
[The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Mini-International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760)

[Interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [—](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Italian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [version.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760) [Psychopharmacol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760)

[2004;24:561–3.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0760)
45. [Otsubo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Tanaka](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Koda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Shinoda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Sano](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Tanaka](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765)
[Aoyama](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Japanese](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765)

[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Mini-International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Interview.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765)
[Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [Neurosci.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765) [2005;59:517–26.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0765)

46. [Mordal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Gundersen,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Bramness](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [JG.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Norwegian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770)
[Mini-International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Interview:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [feasibility,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770)

[acceptability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [test-retest](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [an](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [acute](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770)

[psychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [ward.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Eur](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770) [2010;25:172–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0770)

47. [Kadri](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Agoub](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [El](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Gnaoui](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Mchichi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Alami](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Hergueta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775)
[Moussaoui](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [D.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Moroccan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [colloquial](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Arabic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Mini](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775)

[International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [(MINI):](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [qualitative](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [quantitative](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [validation.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Eur](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775) [2005;20:193–5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0775)

48. [De](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Azevedo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Marques](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [JM,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Zuardi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [AW.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780)
[applicability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Mini](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [International](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Neuropsychiatric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780)

[Interview](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [administered](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [by](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [family](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [medicine](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [residents](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780)

[primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Brazil.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780)

[2008;30:303–10.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0780)


-----

49. [Tejada](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Jaramillo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [LE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Sánchez-Pedraza](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [R.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Revisión](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [crítica](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785)
[sobre](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [los](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [instrumentos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [para](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [evaluación](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [psiquiátrica](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785)

[atención](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [primaria.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Fac](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785) [2014;62:101–10.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0785)

50. [Zigmond](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [AS,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Snaith](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [RP.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Hospital](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790)
[Depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Scale.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Acta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Psychiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [Scand.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790) [1983;67:361–70.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0790)

51. [Snaith](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [RP.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [Availability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [hospital](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795)
[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [(HAD)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [scale.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795) [1992;161:422.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0795)

52. [Moorey](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Greer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Watson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Gorman](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Rowden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800)
[Tunmore](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [factor](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [structure](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [factor](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [stability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800)

[the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [hospital](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [scale](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [patients](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800)

[cancer.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800) [1991;158:255–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0800)

53. [Rico](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [JL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Restrepo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Molina](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [M.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Adaptación](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [validación](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805)
[escala](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [hospitalaria](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [ansiedad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [depresión](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [(HAD)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [una](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805)

[muestra](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [pacientes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [con](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [cáncer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [instituto](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [nacional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805)

[cancerología](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Colombia.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Avances](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805) [Medición.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805)

[2005;3:73–86.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0805)
54. [Hinz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Finck](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Gómez](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Daig](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [I,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Glaesmer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Singer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [S.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810)
[Anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [general](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [population](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810)

[Colombia:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [reference](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [values](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Hospital](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810)

[Depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Scale](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [(HADS).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Soc.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [Psychiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810)

[Epidemiol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810) [2014;49:41–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0810)

55. [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [JBW.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815)
[Questionnaire-2:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [two-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [screener.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815)

[Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [Care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815) [2003;41:1284–92.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0815)

56. [Löwe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [Gräfe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [K.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [Detecting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [monitoring](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820)
[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [two-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [(PHQ-2).](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820)

[Psychosom.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [Res.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820) [2005;58:163–71.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0820)

57. [Manea](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Gilbody](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Hewitt](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [North](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Plummer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825)
[Richardson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Identifying](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [PHQ-2:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825)

[diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825) [2016;203:382–95.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0825)

58. [Inagaki](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Ohtsuki](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Yonemoto](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Kawashima](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Saitoh](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830)
[Oikawa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830)

[(PHQ)-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [PHQ-2](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [general](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [internal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [medicine](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830)

[care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [at](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Japanese](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [rural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [hospital:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [cross-sectional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [study.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830)

[Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830) [2013;35:592–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0830)

59. [Mitchell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [AJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Yadegarfar](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Gill](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Stubbs](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [B.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Case](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [finding](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835)
[screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835)

[(PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [PHQ-2)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835)

[diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [meta-analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [40](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [studies.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Br](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [J](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835) [Open.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835)

[2016;2:127–38.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0835)
60. [SPSS](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [Inc.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [PASW](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [Statistics](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [Windows.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [Chicago:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [SPSS](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840) [Inc.;](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840)
[2009.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0840)
61. [Lezama-Meneses](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [S.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [Propiedades](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [psicométricas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [escala](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845)
[de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [Zung](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [para](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [síntomas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [depresivos](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [población](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [adolescente](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845)

[escolarizada](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [colombiana.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [Psychol](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [Av](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [Discip.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845) [2012;6:91–101.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0845)
62. [Mitchell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [AJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [Vaze](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [Rao](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [S.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [Clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850)
[primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [meta-analysis.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [Lancet.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850) [2009;374:609–19.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0850)

63. [Löwe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [JB,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Mussell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Schellberg](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [D,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855)
[Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [K.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Depression,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [anxiety](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [somatization](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855)

[care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [syndrome](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [overlap](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [functional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [impairment.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855)

[Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855) [2008;30:191–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0855)

64. [Stromberg](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Wernering](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Aberg-Wistedt](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Furhoff](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [AK,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860)
[Johansson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [SE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Backlund](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [LG.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [diagnosing](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860)

[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [women](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [visiting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [GPs’](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [drop](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [clinic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860)

[Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [BMC](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Fam](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [Pract.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860) [2008;9:1–11.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0860)

65. [Campo-Arias](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [Oviedo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [HC.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [Propiedades](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [psicométricas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865)

[una](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [escala:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [consistencia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [interna.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [Salud](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865) [Pública.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865)

[2008;10:831–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0865)
66. [Lucke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [JF.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [�](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [�](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [congeneric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [test](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [theory:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [an](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870)
[extension](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [internal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [consistency](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870)

[heterogeneous](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [tests.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [Appl](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [Psychol](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [Meas.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870) [2005;29:65–81.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0870)

67. [Ventura-León](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [JL.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [¿Es](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [el](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [final](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [del](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [alfa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [Cronbach?](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875)
[Adicciones.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875) [2019;31:80–1.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0875)

68. [Baader](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Molina](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Venezian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Rojas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Farías](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880)
[Fierro-Freixeneta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Validación](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [y](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [utilidad](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [la](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880)

[encuesta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [(Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Questionnaire)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [el](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880)

[diagnóstico](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [depresión](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [pacientes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [usuarios](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [atención](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880)

[primaria](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Chile.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Chil](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [Neuropsiquiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880) [2012;50:10–22.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0880)


69. [Chen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Fang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Chiu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Fan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Jin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Conwell](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Y.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885)
[the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [nine-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [screen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885)

[major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Chinese](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [population.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885)

[Asia-Pacific](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885) [2013;5:61–8.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0885)

70. [Kohrt](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [BA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Luitel](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [NP,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Acharya](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Jordans](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [MJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Detection](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890)
[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [low](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [resource](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [settings:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890)

[Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [(PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [cultural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [concepts](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890)

[distress](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Nepal.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [BMC](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890) [2016;16:1–14.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0890)

71. [Gelaye](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [MA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Lemma](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Deyessa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Bahretibeb](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895)

[Shibre](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895)
[for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [East](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Africa.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895)

[Psychiatry](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [Res.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895) [2013;210:653–61.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0895)

72. [Arrieta](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Aguerrebere](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Raviola](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Flores](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Elliott](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900)
[Espinosa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [utility](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900)

[Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [(PHQ)-2](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900)

[diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [rural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Chiapas,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Mexico:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900)

[cross-sectional](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [study.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [Psychol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900) [2017;73:1076–90.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0900)

73. [Lotrakul](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [Sumrithe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [Saipanish](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [R.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [Reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905)
[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [Thai](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [PHQ-9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [BMC](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905) [2008;8:1–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0905)

74. [Liu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [SI,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Yeh](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [ZT,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Huang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [HC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Sun](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [FJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Tjung](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [JJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Hwang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [LC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910)
[Validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910)

[screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [among](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [patients](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Taiwan.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [Compr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910)

[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910) [2011;52:96–101.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0910)

75. [Wittkampf](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Ravesteijn](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Baas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Hoogen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915)
[Schene](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Bindels](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [accuracy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915)
[Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [detecting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [measuring](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915)

[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [severity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [high-risk](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [groups](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915)

[Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915) [2009;31:451–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0915)
76. [Chagas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [MH,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Tumas](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [V,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Rodrigues](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [GR,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Machado-de-Sousa](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [JP,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920)
[Filho](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [AS,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Hallak](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [JE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [internal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [consistency](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920)

[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920)

[parkinson’s](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [disease.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Age](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [Ageing.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920) [2013;42:645–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0920)

77. [Astivia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [OLO,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Zumbo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [BD1.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Population](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [models](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [simulation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925)
[methods:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [case](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Spearman](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [rank](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [correlation.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925)

[Math.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Stat.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [Psychol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925) [2017;70:347–67.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0925)
78. [Youden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [WJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [Index](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [rating](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [tests.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930) [Cancer.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930)
[1950;3:32–5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0930)
79. [Xu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Wang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Fang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Y.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [model-free](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [estimation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935)
[covariate-adjusted](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Youden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [index](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [its](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [associated](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935)

[cut-point.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Stat.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935) [2014;33:4963–74.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0935)

80. [Inácio](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Carvalho](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [V,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Carvalho](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Branscum](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [AJ.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940)
[Nonparametric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Bayesian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [covariate-adjusted](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [estimation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940)

[the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Youden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [index.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [Biometrics.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940) [2017;73:1279–88.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0940)

81. [Yin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [Tian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [L.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [Joint](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [confidence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [region](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [estimation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [area](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945)
[under](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [ROC](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [curve](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [Youden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [index.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [Stat.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945)

[2014;33:985–1000.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0945)
82. [Li](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [Chen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [Qin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [G.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [Partial](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [Youden](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [index](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [its](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [inferences.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950)
[Biopharm.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [Stat.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950) [2019;29:385–99.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0950)

83. [Lamers](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Jonkers](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [CC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Bosma](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Penninx](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [BW,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Knottnerus](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [JA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955)
[van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Eijk](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [JT.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Summed](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [score](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955)

[Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [was](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [reliable](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [valid](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [method](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955)

[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [chronically](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [ill](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [elderly](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [patients.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955)

[Clin.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [Epidemiol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955) [2008;61:679–87.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0955)

84. [Kleinman](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [Culture](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [depression.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [N.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [Engl.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960)
[2004;351:951–3.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0960)
85. [Campo-Arias](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Oviedo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [HC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Herazo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [E.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Estigma:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [barrera](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [de](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965)
[acceso](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [servicios](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [en](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [salud](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [mental.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Rev](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Colomb](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965) [Psiquiatr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965)
[2014;43:162–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0965)
86. [Phillips](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [MR,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Pearson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [V,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Li](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Xu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Yang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [L.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Stigma](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970)
[expressed](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [emotion:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [study](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [people](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [schizophrenia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [their](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [family](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [members](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [China.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970)

[2002;181:488–93.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0970)
87. [Nakku](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [JEM,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Rathod](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [SD,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Kizza](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [D,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Breuer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Mutyaba](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Baron](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975)
[EC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [accuracy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Luganda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975)

[version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [9-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [2-item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975)

[Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [detecting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [disorder](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975)

[rural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Uganda.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Glob](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Ment](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [Heal.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975) [2016;3:e20.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0975)


-----

88. [Bhana](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Rathod](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [SD,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Selohilwe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [O,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Kathree](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [T,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Petersen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [I.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980)
[validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980)

[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [chronic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [patients](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980)

[South](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Africa.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [BMC](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980) [2015;15:1–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0980)

89. [Hanlon](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Medhin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Selamu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Breuer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Worku](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985)
[Hailemariam](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [brief](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985)

[questionnaires](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [detect](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985)

[Ethiopia.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985) [2015;186:32–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0985)

90. [Muramatsu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Miyaoka](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [H,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Kamijima](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Muramatsu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990)
[Tanaka](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Hosaka](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Performance](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Japanese](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990)
[version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [(J-PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990)

[depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [care.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990)

[2018;52:64–9.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0990)
91. [Dros](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Wewerinke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Bindels](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [PJ,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [van](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Weert](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [HC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Arroll](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995)
[Goodyear-Smith](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Validation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [PHQ-2](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [PHQ-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995)

[screen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [population.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995)

[Ann](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Fam](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995) [2010;7:348–53.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref0995)

92. [Kerr](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [LK,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [Kerr](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [LD](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [Jr.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [Screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [tools](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000)
[care:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [effects](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [culture,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [gender,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [somatic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [symptoms](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000)

[on](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [detection](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [depression.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [West.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000)

[2001;175:349–52.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1000)
93. [Wang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [W,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Bian](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Q,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Zhao](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Y,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Li](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [X,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Wang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [W,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Du](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Reliability](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005)
[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [validity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Chinese](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [version](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005)

[Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [(PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [general](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [population.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005)

[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005) [2014;36:539–44.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1005)

94. [El-Den](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [Chen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [TF,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [Gan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [YL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [Wong](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [O’Reilly](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [CL.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010)
[psychometric](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [properties](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [tools](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010)

[primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [healthcare](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [settings:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [review.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [Affect.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010)

[Disord.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010) [2018;225:503–22.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1010)

95. [Grimes](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [DA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [Schulz](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [KF.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [Refining](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [clinical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [diagnosis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015)
[likelihood](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [ratios.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [Lancet.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015) [2005;365:1500–5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1015)

96. [Huang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [X,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [Qin](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [Fang](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [Y.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [Optimal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [combinations](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020)
[tests](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [based](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [on](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [AUC.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [Biometrics.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020) [2011;67:568–76.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1020)

97. [Richardson](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [LP,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [McCauley](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [E,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Grossman](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [DC,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [McCarty](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [CA,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025)
[Richards](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Russo](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [JE,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Evaluation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025)

[Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [item](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [detecting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [major](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [among](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025)

[adolescents.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [Pediatrics.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025) [2010;126:1117–23.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1025)

98. [Salaminios](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Duffy](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Ades](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Araya](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Button](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [KS,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Churchill](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)
[R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [randomised](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [controlled](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [trial](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [assessing](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [severity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [duration](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [symptoms](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [associated](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)
[clinically](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [significant](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [response](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [sertraline](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [versus](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [placebo,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)


[in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [people](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [presenting](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [to](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [depression](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)
[(PANDA](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [trial):](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Study](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [protocol](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [randomised](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [controlled](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)

[trial.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [Trials.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030) [2017;18:496.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1030)

99. [Oneib](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [B,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Sabir](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Abda](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [N,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Ouanass](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Epidemiological](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [study](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035)
[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [prevalence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [disorders](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [primary](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035)

[care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Morocco.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [J](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Neurosci](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Rural](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [Pract.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035) [2015;6:477.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1035)

100. [Buderer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [NM.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [Statistical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [methodology.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [I.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [Incorporating](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040)
[prevalence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [disease](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [into](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [sample](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [size](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [calculation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040)

[sensitivity](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [specificity.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [Acad.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [Emerg.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040) [1996;3:895–900.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1040)

101. [Obuchowski](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [NA.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [Sample](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [size](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [calculation](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [studies](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [test](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045)
[accuracy.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [Stat.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [Methods](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [Med.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [Res.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045) [1998;7:371–92.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1045)

102. [Beam](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [A.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [Strategies](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [improving](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [power](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050)
[radiology](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [research.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [Am.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [Roentgenol.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050) [1992;159:631–7.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1050)

103. [Hanlon](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Semrau](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Alem](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Abayneh](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Abdulmalik](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [J,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055)
[Docrat](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Evaluating](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [capacity-building](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055)

[health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [system](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [strengthening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [low-](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [middle-income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055)

[countries](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [service](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [users](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [caregivers,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [service](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [planners](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [researchers.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Epidemiol](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Psychiatr](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [Sci.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055) [2018;27:3–10.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1055)

104. [Thornicroft](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [G,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Ahuja](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Barber](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Chisholm](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [D,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Collins](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [PY,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060)
[Docrat](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Integrated](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [care](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [people](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [with](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [long-term](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060)

[mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [physical](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [conditions](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [low-income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060)

[middle-income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [countries.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Lancet](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060) [2018;6:174–86.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1060)

105. [Manea](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [L,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Gilbody](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [S,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [McMillan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [D.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [A](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [diagnostic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [meta-analysis](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065)
[of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Questionnaire-9](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [(PHQ-9)](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [algorithm](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065)

[scoring](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [method](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [as](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [screen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [depression.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065)
[Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065) [2015;37:67–75.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1065)

106. [Sharan](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [P,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Sagar](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Kumar](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [S.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [policies](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [in](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070)
[South-East](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Asia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [the](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [public](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [role](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [of](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [screening](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070)
[instruments](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [depression.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [WHO](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [South-East](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Asia](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [J](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [Public](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070)

[Heal](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [[Internet].](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070) [2017;6:5.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1070)

107. [Hanlon](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [C,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Fekadu](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [A,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Jordans](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [M,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Kigozi](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [F,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Petersen](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [I,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075)
[Shidhaye](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [R,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [et](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [al.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [District](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [mental](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [healthcare](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [plans](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [for](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [five](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075)

[lowand](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [middle-income](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [countries:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [commonalities,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [variations](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075)

[and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [evidence](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [gaps.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Br.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [J.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [2016;208](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [Suppl.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075) [56:47–54.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1075)

108. [Kroenke](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [K,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Spitzer](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [RL,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Williams](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [JB,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Löwe](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [B.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [The](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Patient](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080)
[Health](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Questionnaire](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Somatic,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Anxiety,](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [and](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Depressive](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080)

[Symptom](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Scales:](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [a](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [systematic](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [review.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Gen.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Hosp.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080) [Psychiatry.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080)
[2010;32:345–59.](http://refhub.elsevier.com/S2530-3120(21)00025-4/sbref1080)


-----

